

ASX Announcement

25 January 2023

Resignation of Non-Executive Director

Cogstate Limited (ASX:CGS) advises that Mr David Dolby has today resigned as a non-executive director of Cogstate Ltd.

Mr Dolby stated, “The Dolby family has been extremely pleased to be a long-term investor and active participant over many years in Cogstate as it developed its path-breaking advances in cognitive assessment technology and its related lines of business. The family could not be more proud of the work everyone at the Company has achieved and we remain committed supporters of Cogstate. I have the utmost respect for the Cogstate Board and management team and I am confident of their future success.”

“My family has engaged in a robust program of supporting organizations that are working on discovering and understanding the root causes of Alzheimer’s disease and neurodegeneration, to better characterize disease progression and to develop disease modifying therapeutics. Cogstate continues to serve an important role in serving this ecosystem of research. As a part of my family’s estate planning, we are planning to gift substantially all of our Cogstate shares to the Dagmar Dolby Fund, a California based charitable foundation, and one of our family’s primary vehicles for charitable giving.”

Cogstate Chairman, Martyn Myer thanked Mr Dolby for his efforts, “David joined the Board of Cogstate more than nine years ago when his family made a significant financial investment in Cogstate. Along with the Board and management of Cogstate, David and his family share a vision for a future when measurement of cognition is a normal and critical part of healthcare that provides for earlier identification of impairment and therefore better health outcomes. The proposed gift that the Dolby family is planning to make to the Dagmar Dolby Fund is extraordinarily generous and will provide long term funding for important research.”

The Dagmar Dolby Fund will not be seeking a seat on the Board of Cogstate Ltd.

For the purposes of ASX Listing Rule 15.5, Cogstate confirms that this document has been authorised for release to ASX by a sub-committee of the Board.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O’Connor, Chief Executive Officer, boconnor@cogstate.com